CryoFluor Therapeutics

CryoFluor Therapeutics is a biotechnology company dedicated to discovering and developing next-generation small molecule therapeutics by leveraging advanced cryo-electron microscopy (cryo-EM). The company focuses on challenging membrane protein targets, particularly the Transient Receptor Potential (TRP) channel family, which plays a critical role in sensory signaling and pain. Co-founded by world-renowned structural biologists from UCSF, CryoFluor utilizes high-resolution structural insights to design highly selective modulators for complex ion channels. Their approach aims to address significant unmet needs in chronic pain and inflammatory diseases where traditional drug discovery methods have struggled with off-target effects. By visualizing drug-target interactions at the atomic level, the company seeks to transform the treatment landscape for sensory-related disorders.